MIRA Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $32.1M
- Price
- $0.7636
- % Change (Daily % change from the live per-ticker quote feed.)
- +7.53%
- Volume
- 116.7K
About
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Quick stats
Shares outstanding42.0M
Computed float29.2M
Float / shares69.5%
Key info
SectorHealthcare
IndustryDrug Manufacturers - General
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001904286
AI Summary
AI-generated1/11
standardbullishclinical trial
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
MIRA Pharmaceuticals reported positive toxicokinetic results from a 7-day repeated-dose study of its obesity candidate SKNY-1 in Beagle dogs, demonstrating dose-dependent systemic exposure and rapid absorption.
The findings support dose selection for the upcoming GLP toxicology program and bolster the IND-enabling pathway for the oral obesity treatment candidate.
SKNY-1 has demonstrated the ability to reduce weight while preserving lean body mass in preclinical models and is not classified as a controlled substance by the DEA.